ING Groep NV increased its holdings in shares of Opko Health Inc. (NASDAQ:OPK) by 121.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,168 shares of the biotechnology company’s stock after buying an additional 39,000 shares during the period. ING Groep NV’s holdings in Opko Health were worth $349,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also made changes to their positions in OPK. Kovack Advisors Inc. purchased a new position in Opko Health in the 4th quarter valued at $671,000. IFP Advisors Inc raised its holdings in shares of Opko Health by 37.1% during the 4th quarter. IFP Advisors Inc now owns 1,963,601 shares of the biotechnology company’s stock worth $9,622,000 after acquiring an additional 531,088 shares during the period. Smith Graham & Co. Investment Advisors LP raised its holdings in shares of Opko Health by 2.0% during the 4th quarter. Smith Graham & Co. Investment Advisors LP now owns 607,102 shares of the biotechnology company’s stock worth $2,975,000 after acquiring an additional 11,720 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of Opko Health during the 4th quarter worth $144,000. Finally, RK Asset Management LLC raised its holdings in shares of Opko Health by 8.4% during the 4th quarter. RK Asset Management LLC now owns 932,752 shares of the biotechnology company’s stock worth $4,570,000 after acquiring an additional 72,209 shares during the period. Hedge funds and other institutional investors own 22.71% of the company’s stock.
Several research analysts have recently commented on the company. Zacks Investment Research lowered Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday. Cantor Fitzgerald set a $20.00 price target on Opko Health and gave the stock a “buy” rating in a report on Thursday, March 1st. JPMorgan Chase & Co. lowered Opko Health from a “neutral” rating to an “underweight” rating and set a $7.00 price target on the stock. in a report on Friday, March 2nd. ValuEngine lowered Opko Health from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Finally, BidaskClub downgraded Opko Health from a “sell” rating to a “strong sell” rating in a research report on Wednesday, January 10th. Four research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.25.
Shares of Opko Health Inc. (OPK) opened at $3.42 on Wednesday. The company has a current ratio of 1.14, a quick ratio of 0.98 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1,980.54, a PE ratio of -6.11 and a beta of 1.60. Opko Health Inc. has a 52-week low of $2.66 and a 52-week high of $8.54.
In other Opko Health news, CEO Phillip Md Et Al Frost acquired 50,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was purchased at an average cost of $4.14 per share, with a total value of $207,000.00. Following the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $12,705,457.14. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have purchased a total of 1,225,300 shares of company stock valued at $4,668,947 over the last three months. Corporate insiders own 40.19% of the company’s stock.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.